INTRODUCTION: The alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline has greater efficacy than other pharmacotherapeutic aids for smoking cessation. This presents an opportunity to evaluate the predictive validity of rat models of nicotine taking and relapse. The aim of this study was to evaluate the ability of varenicline to attenuate nicotine self-administration and relapse, as modelled by the reinstatement model of nicotine relapse in rats. MATERIALS AND METHODS: Rats were trained to respond for intravenous nicotine under a fixed ratio schedule of reinforcement. The effects of varenicline (0.3-3.0 mg/kg s.c.) on both nicotine and food self-administration and reinstatement of nicotine seeking were evaluated. RESULTS AND DISCUSSION: Varenicline dose-dependently reduced nicotine self-administration and attenuated both nicotine prime and combined nicotine prime plus nicotine-paired cue-induced reinstatement. Varenicline had no effect on cue-induced reinstatement in the absence of a nicotine prime nor did it induce reinstatement when given alone. CONCLUSION: The effects of varenicline on nicotine-induced reinstatement of drug-seeking are consistent with the demonstrated clinical efficacy of varenicline for smoking cessation.
INTRODUCTION: The alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline has greater efficacy than other pharmacotherapeutic aids for smoking cessation. This presents an opportunity to evaluate the predictive validity of rat models of nicotine taking and relapse. The aim of this study was to evaluate the ability of varenicline to attenuate nicotine self-administration and relapse, as modelled by the reinstatement model of nicotine relapse in rats. MATERIALS AND METHODS:Rats were trained to respond for intravenous nicotine under a fixed ratio schedule of reinforcement. The effects of varenicline (0.3-3.0 mg/kg s.c.) on both nicotine and food self-administration and reinstatement of nicotine seeking were evaluated. RESULTS AND DISCUSSION: Varenicline dose-dependently reduced nicotine self-administration and attenuated both nicotine prime and combined nicotine prime plus nicotine-paired cue-induced reinstatement. Varenicline had no effect on cue-induced reinstatement in the absence of a nicotine prime nor did it induce reinstatement when given alone. CONCLUSION: The effects of varenicline on nicotine-induced reinstatement of drug-seeking are consistent with the demonstrated clinical efficacy of varenicline for smoking cessation.
Authors: Douglas E Jorenby; J Taylor Hays; Nancy A Rigotti; Salomon Azoulay; Eric J Watsky; Kathryn E Williams; Clare B Billing; Jason Gong; Karen R Reeves Journal: JAMA Date: 2006-07-05 Impact factor: 56.272
Authors: H Rollema; L K Chambers; J W Coe; J Glowa; R S Hurst; L A Lebel; Y Lu; R S Mansbach; R J Mather; C C Rovetti; S B Sands; E Schaeffer; D W Schulz; F D Tingley; K E Williams Journal: Neuropharmacology Date: 2006-12-08 Impact factor: 5.250
Authors: Andrea T Alleweireldt; Kenneth F Kirschner; Camille B Blake; Janet L Neisewander Journal: Psychopharmacology (Berl) Date: 2003-01-09 Impact factor: 4.530
Authors: Xiu Liu; Anthony R Caggiula; Matthew I Palmatier; Eric C Donny; Alan F Sved Journal: Psychopharmacology (Berl) Date: 2007-10-12 Impact factor: 4.530
Authors: Thomas J Hopkins; Laura E Rupprecht; Matthew R Hayes; Julie A Blendy; Heath D Schmidt Journal: Neuropsychopharmacology Date: 2012-06-06 Impact factor: 7.853
Authors: Bernard Le Foll; Munmun Chakraborty-Chatterjee; Shaul Lev-Ran; Chanel Barnes; Abhiram Pushparaj; Islam Gamaleddin; Yijin Yan; Maram Khaled; Steven R Goldberg Journal: Int J Neuropsychopharmacol Date: 2011-09-23 Impact factor: 5.176
Authors: R Christopher Pierce; Charles P O'Brien; Paul J Kenny; Louk J M J Vanderschuren Journal: Cold Spring Harb Perspect Med Date: 2012-06 Impact factor: 6.915
Authors: Janice C Froehlich; Emily R Nicholson; Julian E Dilley; Nick J Filosa; Logan C Rademacher; Teal N Smith Journal: Alcohol Clin Exp Res Date: 2017-07-10 Impact factor: 3.455
Authors: Jack E Henningfield; Tracy T Smith; Bethea A Kleykamp; Reginald V Fant; Eric C Donny Journal: Psychopharmacology (Berl) Date: 2016-10-21 Impact factor: 4.530
Authors: Sarah J Cross; Daisy D Reynaga; Michelle Cano; James D Belluzzi; Nurulain T Zaveri; Frances M Leslie Journal: Neuropharmacology Date: 2019-11-06 Impact factor: 5.250